MARKET

MYMD

MYMD

Mymd Pharmaceuticals Inc
NASDAQ
2.400
-0.100
-4.00%
After Hours: 2.270 -0.13 -5.42% 19:52 04/12 EDT
OPEN
2.350
PREV CLOSE
2.500
HIGH
2.500
LOW
2.300
VOLUME
126.96K
TURNOVER
0
52 WEEK HIGH
70.50
52 WEEK LOW
2.070
MARKET CAP
5.18M
P/E (TTM)
-0.4337
1D
5D
1M
3M
1Y
5Y
Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Tilray Brands, Inc. (NASDAQ:TLRY) fell sharply during Tuesday's session. The company missed third-quarter estimates and said it no longer expects to generate positive free cash flow for the full fiscal year 2024. Laser Photonics Corporation shares climbed 168% to $3.82.
Benzinga · 5d ago
Molecular Templates, Acorda Therapeutics, MyMD Pharmaceuticals among healthcare movers
Molecular Templates, Acorda Therapeutics, MyMD Pharmaceuticals among healthcare movers. S&P 500 Health Care Sector +0.11% to 1666.38. Pharmaceuticals, Biotechnology & Life Science contributes 58% to index.
Seeking Alpha · 5d ago
MyMD Pharmaceuticals Filing From Late Monday Shows Co. Entered Omnibus Waiver And Amendment Agreement With Required Holders Under Previously Announced Securities Purchase Agreement
MyMD Pharmaceuticals, Inc. Entered into a Securities Purchase Agreement with certain accredited investors on February 21, 2023. The Company agreed to sell to the Holders shares of the Company's Series F Convertible Preferred Stock. The holders of the Preferred Shares will be entitled to vote with the holders of common stock.
Benzinga · 5d ago
Why Is Vivos Therapeutics (VVOS) Stock Up 16% Today?
Vivos Therapeutics stock is up 15.5% as of Tuesday morning. The company has received full reimbursement for devices for obstructive sleep apnea through Medicare. Vincerx Pharma, MyMD Pharmaceuticals and Trump Media & Technology stock are also in the news.
Investorplace · 5d ago
Why Is Vincerx Pharma (VINC) Stock Down 64% Today?
Vincerx Pharma’s cancer treatments did so potential in preliminary study results. Seven of the 15 VNC-236-101 patients achieve stable disease. The company believes there is more potential for the treatment. VINC stock is down 64.4% as of Tuesday morning.
Investorplace · 5d ago
Why Is MyMD Pharmaceuticals (MYMD) Stock Up 35% Today?
MyMD Pharmaceuticals (NASDAQ:MYMD) stock is up 35.3% on Tuesday. The company announced a new amendment to a securities purchase agreement with preferred shareholders. MYMD stock has more than 4 million shares changing hands as of Tuesday morning. Biophytis stock is also up 43% in the pre-market today. We have all of the hottest stock market news for Tuesday.
Investorplace · 5d ago
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Acrivon Therapeutics (NASDAQ:ACRV) stock moved upwards by 72.3% to $10.19 during Tuesday's pre-market session. MyMD Pharmaceuticals stock rose 33.85% and Addex Therapeutic stock rose 24.48% during the same session. Other gainers included Vincerx Pharma, Neogen and Tilray Brands.
Benzinga · 5d ago
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Pre-market stock movers are worth checking out on Tuesday morning. Biophytis stock is rocketing close to 50% after announcing its 2023 results. Moving stocks this morning are earnings reports, clinical trial data and more. Biggest Pre-Market Stock Movers include 10 top gainers and 10 top losers.
Investorplace · 5d ago
More
About MYMD
MyMD Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. The Company’s MYMD-1 is a drug platform based on a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. It also shows potential as an anti-fibrotic and anti-prolific therapeutic. The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. Supera-CBD is a synthetic, preclinical cannabidiol derivative that has been demonstrated to effectively target cannabinoid type 2 (CB2) receptors. Supera-CBD binds to and inhibits opioid receptors, comparing it side by side with plant-based cannabidiol (CBD).

Webull offers MyMD Pharmaceuticals Inc stock information, including NASDAQ: MYMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MYMD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MYMD stock methods without spending real money on the virtual paper trading platform.